Fast, quantitative, comprehensive!


TMIC is North America’s premiere single source destination providing fee-for-service metabolic profiling. We offer a broad range of custom metabolomics services to fill any need. If you want the fastest, most quantitative and comprehensive metabolomics facility on the continent, you’re at the right place.

Find a service »



Metabolomics is an emerging field of "omics" research specializing in the near global analysis of small molecule metabolites found in living organisms. Its applications are already being seen in a broad range of disciplines including disease diagnostics, agriculture food and safety, and pharmaceutical R&D.

See the technology »



Vital to metabolomics research is the ability to share it with the wider community. Since 2006, the Wishart lab at the University of Alberta has made its research publicly available, developing metabolomic databases, programs and web servers accessed by researchers and private sector partners worldwide.

Available software »

Upcoming Workshop: Metabolomics in Personalized Medicine


April 15, 2017

The Metabolomics in Personalized Medicine: From Theory to Practice workshop will be held on June 8th, 2017 in Toronto at Mount Sinai Hospital. This free one-day event will headline talented presenters from diverse disciplines and should not be missed. Organizers are Dr. David Wishart at The Metabolomics Innovation Centre (TMIC) at the University of Alberta, and Biocrates Life Sciences phenotyping company.

For registration, please email your name, affiliation, and areas of research interest to

Lu Deng receives coveted Mitacs Award

November 16, 2016

Our very own Lu Deng, postdoctoral fellow with University of Alberta’s Department of Computing Science and Department of Biological Sciences, has been rewarded for her achievements. She has won the Mitacs & National Research Council-IRAP Award for Commercialization 2016.

Lu’s research was conducted during her Mitacs Elevate fellowship with Edmonton-based Metabolomic Technologies Inc. (MTI). She developed PolypDx, an inexpensive urine test used to screen for polyps, the precursor to colon cancer.

Previous screening had to be done on cost-prohibitive highly specialized equipment. With the development of PolypDx, medical laboratories in Canada and the U.S. can now proceed using pre-existing mass-spectrometer technology. The product was launched in the spring and has already been in use for months in labs across the U.S.

Lu has completed her Mitacs fellowship and has moved on to a full-time senior scientist position at MTI. We wish her well.

Canadian Government announces new federal funding for metabolomics!


Janurary 22, 2015

$3 million of new federal funding – that’s how much the Canadian government values the cutting-edge metabolomics research being done at Genome Alberta and the University of Alberta, world leaders in the emerging metabolomics market.

The money will buy a 700 MHz Nuclear Magnetic Resonance machine and a Quadrupole-Time of Flight Mass Spectrometer. This equipment will enable scientists to speed up the process of commercializing their discoveries in biomarker research. The goal is to devise medical testing procedures that are less invasive, more accurate, and cheaper to use.

A new research and development medium will also be born, dubbed The Metabolomics Technology Demonstration Centre. Dr. David Wishart, professor at the departments of Biological Sciences and Computing Science, University of Alberta and one of the lead researchers in the project, had this to say: "The Metabolomics Technology Demonstration Centre will provide Canadian researchers with cutting-edge infrastructure and technical expertise to support translation of innovative biomarker discoveries into real life applications. We are very excited to work with our collaborators to develop prototype tools and products that will be implemented and commercialized through industry partnerships."

The government’s research agency, the National Institute of Nanotechnology, is not the only sponsor of this research. Other investors include Alberta Innovates Health Solutions, Metabolomics Technologies Inc. (MTI), and Genome Canada.